Effective July 1, 2026, MassHealth-affiliated plans (Tufts Health Together, Tufts Health Plan Senior Care Options, and Tufts Health One Care) will no longer cover anti-obesity medications including Wegovy, Zepbound, Saxenda, and others when used specifically for obesity treatment. GLP-1 medications will still be covered for diabetes, cardiovascular disease, MASH, and sleep apnea but will require new prior authorizations.
Get alerts when payers change rules like this one
We check Harvard Pilgrim Health Care and other payers every day and email you when a change matches your specialty and state.
01Billing team must identify all patients on anti-obesity medications covered by Tufts Health plans and coordinate with providers to either switch patients with diabetes/prediabetes to antidiabetic GLP-1s or resubmit prior authorizations for approved non-obesity indications (cardiovascular disease, MASH, sleep apnea).
02Before June 30, 2026: Update billing system to flag these medications as requiring prior authorization for non-obesity indications only.
03For Tufts Health Together members, prioritize Wegovy over Zepbound as preferred drug.
If missed: Failure to obtain proper prior authorization will result in claim denials after July 1, 2026.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.